Myray Medical
Company Profile:Shenzhen Myray Bio-Medical Electronics Co. Ltd. is mainly engaged in the research and development, manufacturing, marketing and service of medical devices.In 1991, Myray Medical was founded in Shekou, Shenzhen.In 2006, the company was successfully listed on the New York Stock Exchange in the U.S.A. In 2018, the company landed on the Growth Enterprise Market (GEM) and created the largest IPO.In 2022, the company was ranked 1083 on the Forbes 2022 Global Enterprise 2000 list, ranked No. 1083.
Business Segments
1. In 2021, the company realized operating income of 25.270 billion yuan, up 20.18% year-on-year. Net profit of 8.002 billion yuan, up 20.19% year-on-year.
2, by different products, of which the life information and support products realized revenue of 11.153 billion yuan, in vitro diagnostic products revenue of 8.449 billion yuan. The revenue of medical imaging products was 5.426 billion yuan. The revenue of other products was 230 million yuan, and the revenue of other business was 0.01 billion yuan.
Products
★The life information and support field mainly includes a series of instruments and solutions for life information detection and support, such as monitors, ventilators, defibrillators, anesthesia machines and so on. As the epidemic demand for the largest areas also benefited from the expansion of large public hospitals, the business has maintained good growth in the past two years. Among the monitor 2021 production of 271,100 units, sales of 277,200 units.
★In vitro diagnostic products, on the other hand, include blood cell analyzers, chemiluminescent immunoassay analyzers, biochemical analyzers, etc., which are mainly used to obtain clinical diagnostic information through the testing of human blood, body fluids, tissues and other samples. Automated, intelligent and standardized solutions have also been introduced in recent years.In 2021, the production of in vitro diagnostic analyzers was 54,700 units, with sales of 55,100 units.
★The medical imaging field includes ultrasound diagnostic systems and digital X-ray imaging systems. It provides solutions for radiology, gynecology and obstetrics, emergency medicine, anesthesia and other fields. Color ultrasound products produced 34,700 units and sold 33,200 units in 2021.
Core Executives
Li Xiting: born in 1951, graduated from the University of Science and Technology of China, Department of Physics, majoring in low-temperature physics, the current chairman of the board of directors of Myriad Healthcare, presided over the founding of Myriad Healthcare. 1976 to 1981 worked at the Wuhan Institute of Physics in the field of physics research, 1981 to 1984 worked at the French Center for Scientific Research as a visiting scholar. From 1984 to 1987, he worked at the Wuhan Institute of Physics as a physics researcher, and from 1987 to 1991, he worked at Shenzhen Anke High-Tech Co. Ltd. from 1987 to 1991. In 1991, he founded Myriad Medical International, and in 1999, he founded Myriad Limited.
Hang Xu, born in 1962, received a bachelor's degree in computer science from Tsinghua University, a master's degree in electrical engineering from Tsinghua University, and an EMBA from China Europe Business School. Mr. Xu is currently a director and one of the founders of Myriad Medical, and worked at Shenzhen Anke High-Tech Co. From 1987 to 1991, he worked at Shenzhen Anke High Technology Co., Ltd. and co-founded Myriad Medical International in 1991 and Myriad Limited in 1999. He has been a director of Myriad Medical since 1999 and the chairman of the board of directors of Myriad International.
Shareholding structure
The company's shareholding is mainly concentrated in the Li Xiting and shareholding ratio of 29.85% and 27.10%, respectively, the two are acting in concert with each other and the company's real controller. Li Xiting, Xu Hang and Cheng Ming and *** are the same company's founders.
Financial indicators
The company's revenue has been growing steadily over the past two years, with a growth rate of more than 20%. The company's gross profit margin has been maintained at a high level of 65% throughout the year. The gross profit of each product is above 60%. The company's debt ratio in the first half of 2022 was 29.58%, which is a low level. The company's operating cash flow has steadily improved in recent years.
Industry Trends
★Global medical new infrastructure will accelerate the industry development process
In order to enhance the screening and treatment capacity of infectious diseases, the domestic market has entered a phase of increasing the construction of ICU wards, infectious disease hospitals, fever clinics and other aspects of the medical new infrastructure since March 2020. on October 30, 2020, the Ministry of Finance, the National Health Commission advanced the construction of 2021, the Ministry of Health, the Ministry of Finance, the Ministry of Health, the Ministry of Finance, the National Health Commission and the National Health and Safety Commission. Health Commission advanced the 2021 basic public **** health service subsidy budget of about 54.3 billion yuan, aimed at strengthening the grassroots and even county-level hospitals disease prevention and control capacity.
In December 2021, the State Ministry of Finance issued a number of notices on the advancement of the 2022 subsidy fund budget. In total, the subsidy funds available for health in 2022 amounted to 87.251 billion yuan, including 7.989 billion yuan of subsidy funds for comprehensive reform of public hospitals, 4.842 billion yuan of subsidy funds for capacity building of medical and health care institutions, 58.855 billion yuan of subsidy funds to support the construction of basic public **** health, and 15.57 billion yuan of subsidy grants to support the prevention and control of major infectious diseases.
★ Medical consumables centralized banded purchasing entered the normalized implementation stage
On January 28, 2021, the General Office of the State Council issued the "Opinions on Promoting the Centralized Banded Purchasing of Pharmaceuticals to Normalize and Institutionalize the Implementation of the Work," marking that China's centralized purchasing at this stage has moved from the pilot stage to the institutionalized, standardized "normalized "Implementation stage.
★ Global medical device market continues to grow steadily
According to EvaluateMedTech, the global medical device market volume is expected to be about $504.3 billion in 2021, and the compound growth rate of global medical device sales will be 5.6% from 2020-2024, and the market size may reach $594.5 billion in 2024. According to the analysis data of BCG Boston Consulting Group, the global medical device market size of major countries is $483 billion in 2020, and is expected to be $770 billion in 2030, and the compound growth rate of the global market is maintained at 5% from 2020 to 2030.
★ China's medical device foreign trade structure continues to optimize, the quality and efficiency continue to improve
Chinese customs data show that China's total foreign trade in medical devices in 2021 amounted to 134.94 billion U.S. dollars, a year-on-year decline of 18.8%. Among them, the import value of 50.21 billion U.S. dollars, an increase of 18.4%; exports of 84.73 billion U.S. dollars, a decline of 31.5%. By the new crown epidemic prevention and control of the normalization of the impact of masks, medical protective clothing and other anti-epidemic materials demand has fallen back, the decline in trade volume is obvious. The new crown epidemic on the public **** health management and the development of medical products put forward new challenges, which will trigger a new round of innovation and upgrading of domestic anti-epidemic drugs, epidemic prevention supplies, disinfection products, diagnosis and treatment testing equipment and instruments.
Knowledge Refinement
Monitor:A monitor is a device that is mainly used to monitor a patient's physiological parameters and compare them with the set values, and issue an alarm if they are exceeded.
Ventilator:Ventilator is a respiratory support equipment, can play a role in preventing and treating respiratory failure, reduce complications, save and prolong the patient's life. It is commonly used for respiratory failure, emergency resuscitation and so on.
Anesthesia machine: is a kind of anesthesia drug into the patient's bubble, diffusion to the blood after the central nervous system to inhibit the effect of anesthesia effect of the device. It is mainly used to implement general anesthesia, oxygen supply and assisted or controlled respiration for patients.
Defibrillator:A defibrillator is a medical device that applies electric shocks to resuscitate and treat patients with cardiac arrhythmias.
AED: An Automated External Defibrillator (AED) is a portable medical device that can be used by non-professionals to resuscitate patients in cardiac arrest. In cardiac arrest, only in the best rescue time of the "golden four minutes", the use of AED on the patient defibrillation and cardiopulmonary resuscitation, is the most effective way to stop sudden death.
Coagulation analyzer: Used to measure the content of various components in human blood, providing a reliable basis for clinical diagnosis of patients.
Biochemical analyzer: used to measure the body fluids in a particular chemical composition of the instrument, mainly for enzymes, lipids, proteins and non-protein nitrogen and other major categories of testing projects. It adopts the principle of photoelectric colorimetry, with fast measuring speed and high accuracy.
Cell Blood Analyzer:Used for testing blood specimens, it can quantitatively analyze the blood cells and other formed components in the blood and provide relevant information.
Color ultrasound:It is a kind of equipment that uses ultrasound Doppler technology and ultrasound echo principle to collect blood flow movement, collect tissue movement information and imaging of human organs and tissues. Use dry examination of human disease.